Cantabio Pharmaceuticals Inc. (OTCMKTS:CTBO) Is Bubbling With Excitement
tags: CTBO
The monotonous routine that followed Cantabio Pharmaceuticals Inc. (OTCMKTS:CTBO)’s latest crash was finally ended by a peak of trading that has taken the ticker all the way to $3.13. But can CTBO maintain this high?
To put it bluntly, it seems highly doubtful that it can. The reasons for that are myriad and varied, but they all boil down to the simple fact that at a market value of a staggering $84 MILLION, CTBO seems hideously overbought for what it is.
And what it is, at least as far as due diligence is concerned, is your average ordinary OTC Markets underachiever that talks big but hasn’t really showed any facts to back its boastful claims.
Investors are advised to take a look at the company’s latest financial report, in order to gain a basic grasp on CTBO‘s nature:
- Cash & total assets – $100 thousand
- Total Current Liabilities – $188 thousand
- Quarterly Net loss – $65 thousand
True enough, one could argue that those numbers are outdated, and thus unreliable. Then again, that is only the case because CTBO delayed filing its 10-K that was due about a week ago. As unpleasant as such a development may be, without any new information, that is all investors have to go on.
Long story short – CTBO‘s market cap doesn’t match its actual situation. How long will it take for the market to correct that state of developments remains to be seen, and until such a time comes investors may yet manage to make some money out of trading the ticker.
Still, a word of fair warning is certainly in order here – traders who wish to try and capitalize on the opportunity CTBO‘s volatility presents would do well to tread lightly, lest they end up falling in one of the many pitfalls on the way.
